Cipla USA, Inc. recalls
Cipla USA, Inc. is named on 13 recalls in Recall Relay's records since November 2023, from FDA (23 recalled products: FDA lists each product as its own recall); the most recent was September 18, 2026.
All 23 recalled products, newest first.
-
Class IIofficial
Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral SolutionFailed Impurities/Degradation Specifications
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletscGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class IIofficial
Cipla USA, Inc. recalls Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class IIIofficial
Cipla USA, Inc. recalls Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
-
Class IIIofficial
Cipla USA, Inc. recalls Nilotinib CapsulesFailed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
-
Class IIofficial
Cipla USA, Inc. recalls Lanreotide InjectionPresence of Particulate Matter.
-
Class IIIofficial
Cipla USA, Inc. recalls Diclofenac Sodium Topical GelFailed PH Specifications
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
-
Class IIofficial
Cipla USA, Inc. recalls Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness test
-
Class IIofficial
Cipla USA, Inc. recalls Lanthanum Carbonate chewable tabletsFailed stability specifications: Out of specification for hardness test
-
Class IIIofficial
Cipla USA, Inc. recalls Albuterol SulfateFailed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.
-
Class IIofficial
Cipla USA, Inc. recalls Budesonide Inhalation SuspensionLack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
-
Class IIofficial
Cipla USA, Inc. recalls Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.
-
Class IIofficial
Cipla USA, Inc. recalls Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.
-
Class IIofficial
Cipla USA, Inc. recalls Ipratropium Bromide and Albuterol Sulfate Inhalation Solution USPShort fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.
This page groups recalls by the company name the agency printed, so it can include different companies with similar names, and a recall may name a store or distributor rather than the maker. It counts the recalls in Recall Relay's records, not a company's whole history; an FDA recall that lists several products counts once. Open a recall to see its details and the agency's official notice, which is always the final word. Recall Relay isn't affiliated with any agency or with the companies named here.
Severity labels say where they come from: “official” is the agency's own class, “advisory” is based on the agency's safety warning, and “est. risk” is Recall Relay's estimate from the hazard description, not an agency classification.
Hear about the next one
Recall Relay can email you when a new recall mentions Cipla USA, Inc. or any words you choose. Start with a free key (no card needed), then set up alerts on your account page.
Get recall alerts